Table 2.
Correlation analysis of CC16 with clinical measures and immunological serum markers in n = 16 patients treated for SARS-CoV-2 infection.
| SARS-CoV-2 infection | rS | p-value | |
|---|---|---|---|
| subjects, n (%) | 16 (100) | – | – |
| time since diagnosis, days | 31 (15; 38) | 0.797 | 3.69 x 10-4 |
| WHO clinical progression scale, 0-10 | 7 (5; 7) | 0.312 | 0.24 |
| age, years | 54.44 ± 19.93 | 0.423 | 0.10 |
| CRP, ng/ml | 77.02 ± 62.96 | -0.024 | 0.93 |
| IL-6, pg/ml | 43.05 (19.55; 61.65) | 0.196 | 0.48 |
| D-dimer, ng/ml | 2.85 (1.66; 5.83) | 0.302 | 0.32 |
| platelets, 109/L | 220 (126.5; 303.2) | -0.625 | 9.56 x 10-3 |
| leucocytes, 109/L | 9.74 (6.14; 15.9) | -0.191 | 0.48 |
| lymphocytes, 109/L | 1.1 (1.04; 1.15) | -0.300 | 0.68 |
| granulocytes, 109/L | 7.12 (6.25; 14.9) | 0.300 | 0.68 |
| GOT, U/l | 95.9 (54.95; 199.03) | -0.132 | 0.62 |
| GGT, U/l | 336.5 (172.8; 596.8) | -0.104 | 0.70 |
| creatinine, µmol/l | 110 (51.25; 157.5) | 0.471 | 0.07 |
Data was tested for normal distribution using Shapiro-wilk test. Normally distributed data are presented as mean ± standard deviation, non-normally distributed data as median (25th, 75th percentile). Categorical variables are presented as number of subjects (percentages). Statistical significance was tested using Spearman’s rank correlation tests. CRP, C-reactive protein; IL-6, interleukin-6, GOT, glutamate oxaloacetate transaminase, GGT, gamma-glutamyltransferase.